Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
Mark N. Polizzotto, Jacqueline Nordwall, Abdel G. Babiker, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 530-540
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 121
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, et al.
EBioMedicine (2023) Vol. 90, pp. 104545-104545
Open Access | Times Cited: 45
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Daniele Focosi, Fabrizio Maggi, Alessandra D’Abramo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 55-59
Open Access | Times Cited: 20
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
Sammy Huygens, Quincy Hofsink, Inger S. Nijhof, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 2, pp. 206-210
Open Access | Times Cited: 23
Hyperimmune immunoglobulin for people with COVID-19
Catherine Kimber, Sarah J Valk, Khai Li Chai, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 16
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma
Taketomo Maruki, Hidetoshi Nomoto, Noriko Iwamoto, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 8, pp. 793-795
Closed Access | Times Cited: 5
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 5
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Chris Selman, Katherine J. Lee, Kristin N. Ferguson, et al.
Trials (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis
Xiaosheng Liu, Yuelun Zhang, Lianfeng Lu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience
Wu Liu, Zhong‐Han He, Ling Huang, et al.
Advanced Science (2024) Vol. 11, Iss. 23
Open Access | Times Cited: 4
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study
Sammy Huygens, Tim Preijers, Francis Swaneveld, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 4, pp. 497-509
Open Access | Times Cited: 4
Sepsis: the evolution of molecular pathogenesis concepts and clinical management
Zhongxue Feng, Lijun Wang, Jing Yang, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles
Svenja Weiß, Hung-Mo Lin, Eric Acosta, et al.
Journal of Clinical Investigation (2025) Vol. 135, Iss. 6
Open Access
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19
Tayler A. Van Denakker, Arwa Z. Al‐Riyami, Rita Feghali, et al.
Expert Review of Hematology (2023) Vol. 16, Iss. 7, pp. 501-514
Closed Access | Times Cited: 8
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
Thierry Burnouf, Birgit Gathof, Evan M. Bloch, et al.
Transfusion Medicine Reviews (2022) Vol. 36, Iss. 3, pp. 125-132
Open Access | Times Cited: 12
A prediction model for secondary invasive fungal infection among severe SARS-CoV-2 positive patients in ICU
Lei Su, Tong Yu, Chunmei Zhang, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 2
COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
John F. McDyer, Mahzad Azimpouran, Valerie Durkalski‐Mauldin, et al.
JCI Insight (2023) Vol. 8, Iss. 8
Open Access | Times Cited: 6
Serum anti‐Spike immunoglobulin G levels in random blood donors in Italy: High‐titre convalescent plasma is easier than ever to procure
Daniele Focosi, Silvia Meschi, Sabrina Coen, et al.
Vox Sanguinis (2023) Vol. 118, Iss. 9, pp. 794-797
Closed Access | Times Cited: 6
Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)
Alina Agafina, Valéria Cristina Resende Aguiar, Maria Rossovskaya, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia in Patients Treated With Anti-CD20 Monoclonal Antibodies
Nadav Furie, Michal Mandelboim, Neta S. Zuckerman, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 10
Open Access | Times Cited: 5
Plasma procurement and plasma product safety in light of the COVID‐19 pandemic from the perspective of the plasma industry
Peter L. Turecek, Deborah Hibbett, Thomas R. Kreil
Vox Sanguinis (2022) Vol. 117, Iss. 6, pp. 780-788
Open Access | Times Cited: 9
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far
Hubert Schrezenmeier, Simone Hoffmann, Henrike Hofmann, et al.
Hämostaseologie (2023) Vol. 43, Iss. 01, pp. 067-074
Open Access | Times Cited: 5
The State-of-the-Art of Gene Editing and its Application to Viral Infections and Diseases Including COVID-19
Yousef M. Hawsawi, Anwar Shams, Abdulrahman Theyab, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top